scispace - formally typeset
T

Tommy Rampling

Researcher at University College London Hospitals NHS Foundation Trust

Publications -  44
Citations -  3675

Tommy Rampling is an academic researcher from University College London Hospitals NHS Foundation Trust. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 18 publications receiving 961 citations. Previous affiliations of Tommy Rampling include University College London & University College Hospital.

Papers
More filters
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

Clinical features and management of human monkeypox: a retrospective observational study in the UK

Hugh Adler, +138 more
TL;DR: The longitudinal clinical course of monkeypox in a high-income setting, coupled with viral dynamics, and any adverse events related to novel antiviral therapies are described, to highlight the urgent need for prospective studies of antivirals for this disease.
Journal ArticleDOI

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Xinxue Liu, +90 more
- 04 Sep 2021 - 
TL;DR: The Com-COV trial as discussed by the authors evaluated vaccine safety, reactogenicity, and immunogenicity of the BNT/ChAd schedule with a 28-day or 84-day prime-boost interval.
Journal ArticleDOI

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair Munro, +314 more
- 02 Dec 2021 - 
TL;DR: The COV-BOOST trial as mentioned in this paper investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to As BNT).